Jump to content

Entospletinib

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Pashihiko (talk | contribs) at 06:06, 15 November 2018. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Entospletinib
Clinical data
Other namesGS-9973
Legal status
Legal status
  • Investigational
Identifiers
  • 6-(1H-Indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine
CAS Number
PubChem CID
DrugBank
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H21N7O
Molar mass411.469 g·mol−1
3D model (JSmol)
  • C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6

Entospletinib is an experimental drug for the treatment of various types of cancer under development by Gilead Sciences. It is an inhibitor of spleen tyrosine kinase (Syk).[1] It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).[2]

References

  1. ^ "Definition of entospletinib". NCI Cancer Dictionary. National Cancer Institute.
  2. ^ "Entospletinib - Gilead Sciences". Adis Insight.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Entospletinib&oldid=868912935"